Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CC-1088 Celgene.

Keith Dredge1

  • 1Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia. kdredge@cicr.uq.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|May 26, 2005
PubMed
Summary
This summary is machine-generated.

Celgene was developing CC-1088, a phosphodiesterase 4 inhibitor, for inflammatory diseases and myelodysplastic syndromes. Development was discontinued by April 2005, with CC-10004 becoming the preferred compound.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenografts.

Drug delivery and translational research·2026
Same author

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.

Oncogene·2023
Same author

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.

Journal for immunotherapy of cancer·2023
Same author

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

ACS central science·2022
Same author

A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitis.

Translational research : the journal of laboratory and clinical medicine·2021
Same author

Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.

Biochemical pharmacology·2020
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Pharmacology
  • Drug Development

Background:

  • CC-1088 is a thalidomide analog and phosphodiesterase 4 inhibitor.
  • It was under investigation for inflammatory diseases and myelodysplastic syndromes.

Purpose of the Study:

  • To summarize the development status of CC-1088.

Main Methods:

  • Review of drug development pipeline and company announcements.

Main Results:

  • Celgene discontinued the development of CC-1088 by April 2005.
  • CC-10004 was identified as the preferred compound for further development.

Conclusions:

  • The development of CC-1088 for inflammatory diseases and myelodysplastic syndromes was halted.
  • Celgene shifted focus to CC-10004.